Please assess the completion status of the following clinical trial:

Trial Title: Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and/or cytologically confirmed cervical cancer, meeting 1 of the following criteria:~  * Stage IVB disease~ * Recurrent disease~ * Persistent disease~* Patients previously treated with chemoradiotherapy as initial therapy must demonstrate disease progression~* Measurable disease by physical exam or radiographic studies~* Not amenable to chemoradiotherapy or surgery~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-2~Life expectancy~* At least 6 months~Hematopoietic~* WBC ≥ 3,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT ≤ 2 times upper limit of normal~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.5 mg/dL OR~* Creatinine clearance ≥ 50 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known HIV positivity~* No active infection~* No medical condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon~* No other concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* At least 3 months since prior chemoradiotherapy (6 weeks for patients experiencing disease progression after completion of initial chemoradiotherapy)~* No other prior chemotherapy~Endocrine therapy~* No concurrent hormonal therapy for cancer~Radiotherapy~* See Disease Characteristics~* See Chemotherapy~* Recovered from prior radiotherapy~* No concurrent radiotherapy~Surgery~* Recovered from prior surgery~* No concurrent surgery for cancer~Other~* No prior retinoids~* No other concurrent anticancer therapy~* No other concurrent experimental agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b (Type: EXPERIMENTAL): * Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~* Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~* Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).